Go Pro
NASDAQ:SNOA

Sonoma Pharmaceuticals Q3 2026 Earnings Report

Sonoma Pharmaceuticals logo
$1.21 -0.02 (-1.63%)
As of 02:40 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sonoma Pharmaceuticals EPS Results

Actual EPS
-$0.35
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.06
One Year Ago EPS
N/A

Sonoma Pharmaceuticals Revenue Results

Actual Revenue
$4.35 million
Expected Revenue
$5.47 million
Beat/Miss
Missed by -$1.13 million
YoY Revenue Growth
N/A

Sonoma Pharmaceuticals Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Sonoma Pharmaceuticals' next earnings date is estimated for Wednesday, July 15, 2026, based on past reporting schedules.

Conference Call Resources

Sonoma Pharmaceuticals Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
See More Sonoma Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sonoma Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sonoma Pharmaceuticals and other key companies, straight to your email.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals (NASDAQ:SNOA) is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases. This approach is designed to enhance efficacy while minimizing skin irritation. The company’s lead product, Azclear® Foaming Gel, leverages azelaic acid to address papulopustular rosacea, and is complemented by additional prescription formulations and a suite of over-the-counter cleansers and medicated washes targeting acne-prone skin.

Headquartered in Santa Rosa, California, Sonoma Pharmaceuticals distributes its dermatology portfolio through physician offices, retail pharmacies and online channels across the United States. Under the leadership of President and Chief Executive Officer Mark D. Sirgo, the company is advancing its clinical pipeline and exploring strategic collaborations to expand its product offerings and reach new patient populations.

View Sonoma Pharmaceuticals Profile